TUSC2 Antibody (1550CT388.74.12): sc-517369

TUSC2 Antibody (1550CT388.74.12) is a mouse monoclonal IgG1 kappa light chain antibody that detects TUSC2 protein of human origin by western blotting (WB) and immunoprecipitation (IP). Anti-TUSC2 antibody (1550CT388.74.12) is available as a non-conjugated format. TUSC2, also known as tumor suppressor candidate 2, FUS1, LGCC, or PDAP2, is a 110 amino acid protein predominantly expressed in the kidney, pancreas, lung, heart, and skeletal muscle, where TUSC2 plays a crucial role as a tumor suppressor. TUSC2′s primary function involves inhibiting invasive colony formation by inducing G1 cell cycle arrest, which ultimately leads to apoptosis and prevents tumor growth. This mechanism is vital in maintaining cellular integrity and preventing cancer progression. The gene encoding TUSC2 is located on human chromosome 3, a region harboring over 1,100 genes, including several key tumor suppressor genes such as RASSF1, which mediates apoptosis, and SEMA3B, which regulates angiogenesis. TUSC2′s significance extends beyond tumor-suppressing capabilities, as alterations in TUSC2 expression have been linked to various genetic diseases associated with chromosome 3, including Marfan Syndrome and von Hippel-Lindau syndrome. Anti-TUSC2 antibody (1550CT388.74.12) can be used to explore the intricate pathways of tumor suppression and broader implications of TUSC2 in human health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TUSC2 Antibody (1550CT388.74.12) References:

1. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.  |  Lerman, MI. and Minna, JD. 2000. Cancer Res. 60: 6116-33. PMID: 11085536
2. Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells.  |  Kondo, M., et al. 2001. Oncogene. 20: 6258-62. PMID: 11593436
3. Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells.  |  Uno, F., et al. 2004. Cancer Res. 64: 2969-76. PMID: 15126327
4. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.  |  Lin, J., et al. 2007. Oncogene. 26: 6989-96. PMID: 17486070
5. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression.  |  Lee, DY., et al. 2007. Proc Natl Acad Sci U S A. 104: 20350-5. PMID: 18077375
6. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer.  |  Prudkin, L., et al. 2008. Clin Cancer Res. 14: 41-7. PMID: 18172250
7. Characterization of a novel platelet-derived growth factor-associated protein.  |  Fischer, WH. and Schubert, D. 1996. J Neurochem. 66: 2213-6. PMID: 8780057